In 2020, the FDA issued final guidance on power morcellators after the devices faced questions about potentially spreading cancer. The agency recommended limiting laparoscopic power morcellation (LPM) to use with certain tissue containment systems. It also only recommended the procedure only for premenopausal, under-50 women who have suspected fibroid tumors.
Moresolution operates in conjunction with the PneumoLiner, which Olympus describes as a first-of-its-kind containment device. The company says its Olympus Contained Tissue Extraction System provides select patients with a laparoscopic surgical option. As a result, it’s a tissue-removal alternative to an open hysterectomy or open myomectomy.
Olympus said Moresolution can cut dense or calcified fibroids. In addition, its efficient cutting may help save operating room time. There’s a lightweight handpiece, safety features including a “cut” or “no cut” mode, and autoclaveable and reusable components.
“We are excited to offer a new power morcellation solution for minimally invasive gynecological procedures,” said Richard Reynolds, president of the Medical System Group at Olympus America.
“Olympus supports the safe use of power morcellators with a contained extraction system according to FDA guidance. This device reflects a response to our customers’ requests for more power and control during the procedure. This particular device works very well on very dense, calcified tissue, which is difficult to cut with other devices,” Reynolds said in a news release.